CACNA1C and acute myeloid leukemia: Therapeutic potential of inhibiting CaV1.2 in AML was revealed in an elegant 3D-culture model that mimicked the human bone marrow niche and utilized AML-derived mesenchymal stromal cells (AML-MSCs) from pediatric patients (138).